Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652281 | 0.94 | ACHE (0.39) | ACHEBCHEMEN1KMT2A | |
| SCHEMBL19658648 | 0.85 | ACHE (0.55) | ACHEBCHECHRM4 | |
| SCHEMBL19652098 | 0.85 | ACHE (0.42) | ACHECHRM4ALDH1A1 | |
| SCHEMBL19652132 | 0.85 | BCHE (0.36) | ACHEBCHEMEN1KMT2AALDH1A1 | |
| SCHEMBL19652115 | 0.83 | ACHE (0.46) | ACHE | |
| SCHEMBL19652095 | 0.81 | ACHE (0.39) | ACHE | |
| SCHEMBL19658464 | 0.79 | ACHE (0.52) | ACHEBCHEMEN1KMT2A | |
| SCHEMBL19652102 | 0.79 | SIGMAR1 (0.36) | BCHEMEN1KMT2A | |
| SCHEMBL19658462 | 0.71 | ACHE (0.38) | ACHEBCHECHRM4ALDH1A1 | |
| SCHEMBL27417087 | 0.71 | CYP1A2 (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | ACHE 2649/4885BCHE 1184/4885CHRM4 2474/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ACHE 2649/4885BCHE 1184/4885CHRM4 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.